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Abstract 
A conjugate of the antineoplastic drug doxorubicin (DXR) with maleylated bovine serum albumin (MBSA) was taken up by a human histiocytic 
lymphoma cell line (U937) through the high efficiency process of scavenger receptor-mediated ndocytosis resulting in a sixfold higher intracellular 
concentration of the drug compared to that obtained when the free drug was administered. Compared to the free drug, the drug conjugate showed 
significantly higher cytotoxicity towards U937 cells presumably because of intracellular availability of a pharmacologically active form of the drug. 
The intracellular product released after lysosomal degradation of the drug conjugate was chromatographically identical to free DXR. These findings 
merit serious consideration in the development of new chemotherapeutic agents for the treatment of histiocytic malignancies. 
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1. Introduction 
Histiocytic malignancies are aggressive neoplastic 
diseases which affect the cells of the mononuclear 
phagocyte system and are usually fatal if untreated. 
Chemotherapy is the main line of treatment for these 
disorders. However, reports of the response to single 
therapeutic modalities in these diseases are fragmentary 
and no well-documented scientific literature is available. 
Although promising results have been obtained when 
treated with combinations of various antitumor drugs 
[l], the toxicity associated with the chemotherapeutic 
agents remains the major limitation of the combination 
therapy. 
Doxorubicin (DXR), an anthracycline antibiotic com- 
monly used in the treatment of histiocytic malignancies, 
causes substantial acute and chronic cardiac toxicity [2], 
thus limiting the usefulness of the drug. The adverse 
effects probably arise due to the fact that at therapeuti- 
cally effective concentrations in the blood, all the cells in 
the body are exposed to the drug. Such side effects could 
be minimised if a modality for the administration of the 
drug could be worked out which would (i) reduce the 
uptake of the drug through nonspecific diffusion-medi- 
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ated processes by the nontarget cells, and (ii) selectively 
deliver the drug only to the target cells at relatively low 
plasma concentrations. Attempts have been made for 
selective delivery of cytotoxic agents exclusively to the 
neoplastic cells using various antibodies, liposomes, 
DNA and growth factors as carriers [3-6] with varying 
degrees of success. 
As an alternative approach, we have been exploring 
the possibility of exploiting the cell-type specificity and 
high efficiency of the scavenger eceptor-mediated endo- 
cytic pathway [7] for selective delivery of drugs to tumor 
cells bearing such receptors. Since this receptor system 
is known to be present primarily on the cells of the 
macrophage/monocyte lineage, it may be possible to 
achieve selective delivery of antitumor agents to the neo- 
plastic cells in histiocytic malignancies through these re- 
ceptors. The scavenger eceptors recognize certain poly- 
anionic macromolecules uch as maleylated albumin, 
polyinosinic acid etc. [7]. Previously, we have shown the 
feasibility of exploiting this receptor system for selective 
elimination of intracellular parasites in cell culture and/ 
or animal models of leishmaniasis and tuberculosis using 
various drug conjugates with maleylated bovine serum 
albumin (MBSA) as a carrier [S-l 11. Recently, we have 
demonstrated that the scavenger eceptor-mediated e- 
livery of daunomycin elicits selective toxicity towards 
murine neoplastic cells of macrophage lineage whereas 
the receptor negative cells remain unaffected, both in 
vitro and in vivo [ 12,131. As a prelude to determining the 
feasibility of extending this approach to human malig- 
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nancies of macrophage origin, it is important to establish 
the efficacy of the approach in an appropriate model 
system. 
Accordingly, in the present investigation we have used 
a well-characterised human cell line U937, derived from 
a histiocytic malignancy that possesses many features of 
cells of monocyte/macrophage lineage. Our results estab- 
lish the superior efficacy of doxorubicin coupled to 
MBSA (MBSA-DXR) in cessation of DNA synthesis by 
U937 cells compared to free DXR. 
2. Materials and methods 
2.1. Materials 
Tissue cultures supplies were from Grand Island Biological Co, 
(Grand Island. NY). Snecial biochemicals like DXR. BSA. chloro- 
quine, monensin, &c&din, dextran sulphate, polyinosinic acid, 
polyguanylic acid, polyadenylic acid, polycytidylic acid, fetuin and hep- 
arin were purchased from Sigma Chemical Co. (St. Louis, MO). 
[14C]DXR hydrochloride and [3H]thymidine were purchased from 
Amersham International (Amersham, UK). Other reagents used were 
of analytical grade. 
2.2. Cells 
U937, a human cell line derived from a patient with histiocytic lym- 
phoma, was obtained from American Type Culture Collection and 
maintained in medium A (RPM1 1640 with 10% heat-inactivated fetal 
calf serum (FCS), 2 mM L-glutamine and gentamycin (50&ml). These 
cells were grown at 37°C in a humidified incubator with 5% CO, and 
95% air atmosphere. 
2.3. Maleylation of BSA 
BSA was maleylated by reacting the protein with maleic anhydride 
at pH 8.0 as described by Glazer et al. [14]. Electrophoretic mobilities 
of the chemically modified protein was tested by 0.7% agarose gel 
electrophoresis at pH 8.4 [15]. 
2.4. Coniugation of DXR to MBSA 
MBSA was coupled to DXR using glutaraldehyde as described pre- 
viouslv 1161. In brief. 6.7 mu of MBSA was mixed with 290 &z of DXR 
in 1 2 of phosphate-buffer;d saline (PBS). Glutaraldehydd (0.5%) was 
added dropwise to the reaction mixture to achieve a final concentration 
of 0.05% and the reaction mixture was stirred for 30 min at room 
temperature. The reaction was stopped by adding 50 ~1 of 1 M lysine 
and the conjugate was separated from low molecular weight reactants 
by Sephadex G-50 column chromatography. Void volume fractions 
containing MBSA-DXR were pooled and subjected to extensive dialy- 
sis. The amount of DXR int he conjugate was determined by measuring 
the absorbance at 495 nm [16]. Protein was estimated by bicinchoninic 
acid (BCA) reagent [17]. Stoichiometric estimation revealed that the 
conjugate contained 34 mol of drug per mol of protein. [14C]DXR 
(snecific activity, 50 mCi/mmol) was diluted with unlabeled DXR to a 
specific activity of 133 cpm/ng of DXR and coupled to MBSA under 
similar reaction conditions. The specific activity the MBSA-[‘4C]DXR 
conjugate was 4 cpm/ng protein, i.e. about 30 pg DXR/ng protein. 
2.5. Radioiodination of MBSA-DXR 
MBSA-DXR was labeled with Na[‘251] by the iodine monochloride 
catalysed reaction as described [181. More than 99% of the radioactivity 
was acid precipitable and the specific activity of the conjugate was 186 
cpm/ng of protein. 
2.6. Uptake and degradation f [“‘I]BSA-DXR by U937 cells at 37” C 
Suspensions containing 1 x lo6 U937 cells in 1 ml of medium B 
(medium A without FCS but with 1 mg/ml of BSA) were placed in each 
well of 24-well tissue culture plate and incubated in the presence of 
various concentrations of [“‘I]MBSA-DXR at 37°C in a humidified 
incubator with 5% CO, and 95% air atmosphere. After 5 h, the cells 
were collected by centrifugation (500 x gfor 10 min), washed twice with 
ice-cold PBS containing 1 mg/ml of BSA and twice with PBS. The cells 
were suspended in 1 ml of 0.1 N NaOH and the amount of radioactivity 
associated with the cells were determined. The amount of TCA soluble 
radioactivity accumulated in the medium during the 5 h incubation 
period was determined in triplicate dishes as described [18]. 
2.7. Cellular uptake of [14C]DXR and MBSA-[“C]DXR by U937 
cells 
Suspensions containing 1 x lo6 U937 cells along with indicated con- 
centrations of [14C]DXR or MBSA-[‘4C]DXR in 1 ml of medium B 
were incubated at 37°C in a humidified incubator with 5% CO*-95% 
air atmosphere. After 30 min, the radioactive medium was removed and 
the cells were washed as described above. The cells from triplicate 
dishes were dissolved in 1 ml 0.1 N NaOH. aliauots (0.5 ml) of the cell 
extract were mixed with 5 ml of aqueous scintillation fluid and the 
radioactivity was measured in a liquid scintillation counter as described 
before [9]. The protein content of the cell extract was determined by the 
BCA method. In competition experiments, cells were incubated with 6.8 
pug MBSA-[‘4C]DXR (200 ng DXR) in presence of indicated concentra- 
tions of DXR and MBSA-DXR and processed as above. 
2.8. HPLC analysis of the intracellular product ajter degradation of
MBSA-[“C]DXR 
U937 cells (5 x 10’) were incubated in 1 ml of medium B containing 
110 ng [14C]DXR in the free or conjugated form at 37°C for 4 h in a 
humidified incubator with 5% CO2 and 95% air atmosphere. The cells 
were washed twice with ice cold PBS containing 1 mg/ml of BSA, 
followed twice by PBS as above. The drug was extracted into chloro- 
form/methanol (2: 1 v/v), evaporated to dryness and reconstituted in 50 
~1 methanol. The samples from the free drug and the conjugate treated 
groups were mixed with 25 pg DXR in a total volume of 100 ~1 and 
analysed by reverse-phase HPLC on a Nova Pack Cl8 (150 x 4 mm) 
column using TFA-acetonitrile solvent system at a flow rate of 1 ml/ 
min. The elution profile was monitored by absorbance at 495 nm and 
the radioactivity present in the fractions (1 ml) were determined using 
a scintillation counter. 
2.9. Cytotoxicity assay in vitro 
The cytotoxicity of the drug conjugate was determined by the 
[‘Hlthymidine incorporation assay [19]. In brief, 1 x lo5 cells were incu- 
bated overnight in 1 ml medium A at 37°C in a humidified incubator 
with 5% CO2 and 95% air atmosphere, washed and incubated in 1 ml 
medium A containing indicated concentrations of DXR in free or 
conjugated form for 30 min at 37°C. The cells were then washed thrice 
with 1 ml of medium A and incubated in 1 ml of drug free medium A 
at 37°C. After 20 h, the cells received [‘Hlthymidine (5 &i/ml). After 
3 h, the cells were harvested using cell harvester, washed and radioactiv- 
ity incorporated by the cells were determined. 
3. Results and discussions 
To determine the nature of interaction with the drug 
conjugate, U937 cells were incubated with increasing 
concentrations of [1251]MBSA-DXR at 37°C for 5 h. Fig. 
la shows that the cell associated radioactivity increased 
in a saturable fashion. During this period, a part of the 
added radioactivity was degraded to TCA-soluble mate- 
rial indicating proteolytic degradation of the drug conju- 
gate (Fig. lb). Half-maximal values for both uptake and 
degradation of [‘251]MBSA-DXR at 37°C were achieved 
at a concentration of approximately 6 pg of protein/ml. 
The saturability of both the uptake and the degradation 
processes becomes even more explicit when the values for 
the uptake and degradation of [‘251]MBSA-DXR in the 
presence of excess MBSA (300 &ml) are substracted 
from the respective total amounts of [‘251]MBSA-DXR 
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Fig. 1. Concentration dependence of uptake (a) and degradation (b) of [‘*‘I]MBSA-DXR by U937 cells at 37°C. Receptor mediated uptake (A) or 
degradation (A) was obtained by substracting the values for nonsaturable uptake (0) or degradation (0) from the total uptake (0) or degradation 
(0). Results are expressed as ng of MBSA-DXR associated with the cells or degraded per mg of cell protein (mean f SD. for three independent 
experiments). 
associated with the cells or degraded. In order to deter- 
mine if active lysosomal functions are necessary for the 
degradation of the drug conjugate, U937 cells were al- 
lowed to bind [L251]MBSA-DXR at 4°C for 2 h, washed 
extensively to remove unbound radioactivity and the 
cells were incubated in prewarmed (37°C) medium in 
absence or presence of either monensin (25 PM) or chlo- 
roquine (75 PM). After 3 h, the TCA-soluble radioactiv- 
ity released in the medium of each group of cells was 
measured. The amounts of [‘251]MBSA-DXR degraded 
per mg of cell protein under these conditions were as 
follows: untreated control, 449 ? 11; monensin-treated, 
292 + 20; and chloroquine-treated, 160 + 3.6. Thus, ly- 
sosomal inhibitors monensin and chloroquine reduced 
the degradation of [‘*‘I]MBSA-DXR to 65% and 35% of 
that by untreated control cells, respectively, indicating 
that the radiolabeled MBSA-DXR was internalized and 
degraded in the cellular lysosomes in absence of the in- 
hibitors. The data in Fig. 1 also show that the amount 
of TCA-soluble radioactivity accumulated in the me- 
dium after 5 h was 2-3 times higher than the cell-associ- 
ated radioactivity. The facts that lysomotropic agents 
inhibit the degradation of the drug conjugate, taken to- 
gether with the data in Fig. 1 showing saturability of the 
uptake and degradation of the drug conjugate, suggest 
that the binding, internalization and subsequent lyso- 
somal degradation of the drug conjugate are mediated 
through a limited number of binding sites which are 
probably recycled and participate in multiple rounds of 
ligand delivery into the cells. These conclusions are in 
consonance with our previously published results with 
similar drug conjugates [8-131 as well as those of others 
17,181. 
Fig. 2 compares the cellular uptake of the free conju- 
gated DXR as a function of DXR concentration in the 
medium. When the cells were incubated for 30 min in 
presence of [14C]DXR (300 ng/ml) either in free or conju- 
gated form, the cell-associated DXR amounts were 
about 16 ng/mg and 100 ng/mg of cell protein, respec- 
tively. Thus the administration of the drug in the conju- 
gated form resulted in a sixfold higher uptake compared 
to the free drug in the same time interval. Presence of an 
excess of MBSA in the medium effectively prevented the 
uptake of MBSA-[i4C]DXR, whereas free DXR did not 
have any significant effect, indicating that the drug con- 
jugate was recognised by the macrophages through the 
MBSA moiety (data not shown). 
In order to determine whether the enhanced uptake of 
MBSA-DXR was mediated by the scavenger eceptors, 
cells were incubated at 37°C with 6 &ml [1251]MBSA- 
DXR along with various negatively charged compounds 
(6 &ml). The results presented in Table 1 show that 
negatively charged compounds like MBSA, fucoidin, 
dextran sulphate, polyguanylic acid and polyinosinic 
acid that are reported to be recognised by the scavenger 
receptor system, effectively competed for the degrada- 
tion of the [‘251]MBSA-DXR. In contrast, compounds 
not recognised by these receptors, viz. fetuin, polyad- 
enylic acid, polycytidylic acid and heparin were much 
less effective. These data indicate that the drug conjugate 
is taken up by the U937 cells through the scavenger 
receptor system. 
In an attempt o identify the pharmacologically active 
species of the drug released after intracellular degrada- 
tion of the drug conjugate, U937 cells were incubated 
with MBSA-[‘4C]DXR or free [14C]DXR for 5 h, and 
extracted with CHC1&H30H. The materials extracted 
in the solvent were analysed by HPLC. The data pre- 
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Fig. 2. Uptake of different concentrations [“‘CIDXR in free or conju- 
gated form by U937 cells at 37°C. Results are expressed as ng of 
[“‘CIDXR taken up per mg of cell protein (mean f S.D. for three inde- 
pendent experiments). 
sented in the Fig. 3 show that the material obtained from 
the cells treated with MBSA-[‘4C]DXR shows a single 
major peak of radioactivity with the same retention time 
as the authentic unlabelled DXR used as standard. The 
radioactivity from the [14C]DXR treated cell samples was 
also eluted from the column at the same position as that 
of authentic DXR standard (data not shown) indicating 
that incubation with the cells did not alter the mobility 
of DXR. These results suggest hat the product released 
after lysosomal degradation of the conjugate is chroma- 
tographically identical with the free drug. 
To determine the cytotoxic efficacy of the intracellular 
product released after lysosomal degradation of the drug 
conjugate, we have compared the effects of the free and 
conjugated DXR on incorporation of [3H]thymidine by 
U937 cells. The data presented in Fig. 4 show that free 
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DXR (0.3 PM) inhibited about 50% of the [3H]thymidine 
incorporation compared with the untreated control cells. 
In contrast, the same concentration of DXR reduced 
[3H]thymidine incorporation by over 90% in the recep- 
tor-bearing U937 cells. The superior cytotoxic activity of 
the drug conjugate was more pronounced at lower con- 
centrations. Thus, 0.03 PM of the drug in the conjugated 
form reduced 50% of the [3H]thymidine incorporation 
compared with the untreated control, whereas 0.3 ,uM of 
the free drug was needed to achieve the same percentage 
of inhibition. We have previously shown that in receptor- 
negative Bowes melanoma cells only 10% of the [3H]thy- 
midine incorporation was inhibited by the same concen- 
tration of the drug in the conjugated form (data not 
shown; [12]). Time-course studies (data not shown) re- 
vealed that the rate of [3H]thymidine incorporation by 
the U937 cells treated with free DXR (0.2 PM) over a 24 
h experimental period paralleled that in the untreated 
control cells, whereas, the same concentration of DXR 
in the conjugated form arrested the ability of these cells 
to incorporate [3H]thymidine within 2 h of exposure. 
The data presented in this paper show that the conju- 
gation of DXR with MBSA significantly increased the 
cytotoxic activity of the drug to the scavenger eceptor 
bearing U937 cells (Fig. 4). The enhanced antitumor 
efficacy of the drug conjugate is likely to be due to high 
affinity binding of the carrier to the cell surface receptors 
followed by rapid internalization and subsequent degra- 
dation of the carrier in the lysosomes leading to en- 
hanced intracellular release of a pharmacologically ac- 
tive species of the drug. Presumably, the rapid recycling 
of the scavenger eceptors for multiple rounds of ligand 
delivery contribute to the building up of high intracellu- 
lar concentrations of the drug in the target cells when 
MBSA-DXR is used (Fig. 2). Furthermore, the HPLC 
analysis of the intracellular product generated after deg- 
radation of the drug conjugate shows that it is likely to 
be the native DXR (Fig. 3). 
In this study, we have used MBSA as a homing device 
to deliver an antitumor agent (DXR) specifically to 
human neoplastic cells of macrophage origin exploiting 
the scavenger eceptor mediated endocytic pathway. The 
Table 1 
Degradation of [‘ZSI]MBSA-DXR by U937 cells: competition by negatively charged macromolecules 
Effective [“‘IIMBSA-DXR degraded Ineffective [“‘I]MBSA-DXR degraded 
competitor (ng/mg of cellular protein) competitor (ng/mg of cellular protein) 
MBSA 896 + 80 Fetuin 1302 f 42 
Fucoidin 593 f 46 Heparin 1060 f 68 
Dextran sulphate 506 f 2.8 Polyadenylic acid 1346+24 
Polyinosinic acid 386 f 19 Polycytidylic acid 1020 + 11 
Polyguanylic acid 283 + 4.5 
Competition of degradation of [rZ51]MBSA-DXR (6 ,&g/ml) by U937 cells at 37’C was measured in absence or presence of same concentrations 
(6 &ml) of various polyanionic macromolecules. In absence of any competing compound, U937 cells degraded 1613 ng of [‘251]MBSA-DXR per 
mg of cellular protein during 5 h incubation at 37°C. 
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approach of receptor mediated drug delivery to cancer 
cells using various receptor systems for lipoproteins, 
growth factors, etc. has been reported previously [3-61. 
But the ubiquitous distribution of these receptors on 
normal cells is the major drawback for selective delivery 
of the drug specifically to the tumor cells. Nevertheless, 
interesting in vitro results have been obtained using low- 
density lipoprotein as a carrier [ZO]. However, the major 
limitation of this carrier is that only lipophilic drugs can 
be incorporated into the LDL molecules. Moreover, 
lipoproteins are complex molecules with limited stability 
which are difficult to formulate into stable pharmacol- 
ogical preparations. In contrast, MBSA as a drug carrier 
has certain advantages over the existing ones because of 
the simplicity of preparation, longer shelf life, and ease 
of sterilization and formulation into apyrogenic prepara- 
tions. 
These studies, in conjunction with the earlier reports 
[ 12,131 from this laboratory demonstrating superior 
therapeutic potential of MBSA-daunomycin in suppress- 
ing the growth of solid tumors of macrophage lineage in 
BALBlC mice, raise the interesting prospect of using this 
mode of chemotherapeutic approach against neoplastic 
diseases like histiocytic malignancies which are difficult 
to control by conventional chemotherapy. Moreover, 
this receptor system also offers the possibility of manip- 
Fraction f ml f 
10 20 30 
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40 
Fig. 3. Identification of the intracellular product released after degrada- 
tion of the drug conjugate by U937 cells. The sample was taken in 
methanol, mixed with 25pg doxorubicin in a total volume of 100~1 and 
injected to the column (Nova Pack C 18) equiiibrated with solvent A 
(0.1% TFA in water). The run was continued with solvent A for 10 ruin, 
then a gradient of solvent B (80% acetonitrile containing 0.1% TFA) 
was employed as follows: 0 to 30% solvent B in 40 min and 30% to 100% 
in the next 10 min. Elution profile was monitored as described in section 
2. Absorbance, (-); Radioactivity, (0). 
DXR (/IM) 
Fig. 4. Uptake of [‘Hlthymidine by U937 cells in presence of DXR in 
free or in conjugated form. The results are expressed as percentages of 
the uptake of [3H]thymidine by untreated cells (mean + SD. for three 
inde~ndent experiments). 
mating the metabolism of macrophages in order to sup- 
press or enhance immune responses. 
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